Accessibility Menu
Dogwood Therapeutics logo

Dogwood Therapeutics(NASDAQ) VIRI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-99%
1 Year-66%
1 Month+9%
N/A
Dogwood Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.642026-07-31
Dogwood Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.33%USD 1.502026-07-24
1 month+9.33%USD 1.502026-07-01
3 month+12.33%USD 1.462026-05-01
Year to date-60.58%USD 4.162025-12-31
1 year-66.08%USD 4.842025-07-31
3 year-96.53%USD 47.252023-08-01
5 year-98.9%USD 148.752021-07-30
Since inception-99.62%USD 417.752020-12-17

Dogwood Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$12.14B

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 11, 2024

VIRI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dogwood Therapeutics

Dogwood Therapeutics develops medicines for pain and immune-related diseases. Its products aim to help people with nerve pain or long-term viral symptoms. The company focuses on non-opioid treatments for patients with few options.

What’s in the Medicine Cabinet?

  • Halneuron: Non-opioid drug for nerve pain from cancer treatments; targets patients with chemotherapy-induced pain.
  • SP16: Synthetic peptide for nerve damage and inflammation; early testing in breast cancer patients.
  • IMC-1: Combination therapy for fibromyalgia, a chronic pain condition; designed for people with viral-triggered symptoms.
  • IMC-2: Combination therapy for long COVID symptoms like fatigue and pain; targets patients with lingering effects after infection.

Growth Spurts and Strategic Moves

  • Acquired Pharmagesic (Holdings) in October 2024, expanding its drug pipeline.
  • Launched Phase 2b trial for Halneuron in the U.S. in early 2025.
  • Signed exclusive licensing deal for SP16 with Serpin Pharma in September 2025.
  • Raised $11.4 million in January 2026 to extend operations.

Why Dogwood Stands Out (Without Barking)

Dogwood focuses on non-opioid pain relief, addressing a gap in cancer-related nerve pain. Its synthetic drug development aims for cost-effective, consistent manufacturing. The company holds patents that protect its products into the 2030s and 2040s.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; pre-commercial stage.
  • Net loss was $-16 million in QQ3 2025, down from $-2 million in QQ3 2024.
  • Research and development expenses rose 519% to $21.9 million in 2025.
  • Cash used in operations was $-3 million in QQ3 2025, down 259.6% year-over-year.
  • Cash and equivalents were $6.5 million at December 31, 2025, plus $11.4 million raised in January 2026.

Bottom Line

Dogwood has evolved through acquisitions and pipeline expansion, focusing on non-opioid pain therapies. The company remains pre-revenue and relies on external funding for continued development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Gregory Duncan, MBA

Website

www.dwtx.com

Headquarters

Alpharetta, GA 30009, US

VIRI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

28625.09%

Return on Capital

-37342.61%

Return on Assets

12752.22%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$23.54B

EBITDA

-$19.68B

Operating Cash Flow

-$15.52M

Capital Expenditure

$0.00

Free Cash Flow

-$15.52M

Cash & ST Invst.

$13.23M

Total Debt

$144.93K

Dogwood Therapeutics Performance Analysis

Dogwood Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Dogwood Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Dogwood Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -27.66-42.3%
20232023-12-31USD -7.05-74.5%
20242024-12-31USD -12.5277.5%
20252025-12-31USD -7.14-43.0%
Dogwood Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3076.4%
Q32025-09-30-312.1%
Q42025-12-31240.4%
Q12026-03-31-101.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

4

N/A

Net Income

-$4.99M

+100.0%

EBITDA

-$5.08M

+100.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.23M

-24.6%

Total Debt

$144.93K

-99.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$87.62K

-99.9%

Short Term Debt

$57.31K

-99.9%

Return on Assets

127.52%

N/A

Return on Invested Capital

-254.12%

N/A

Free Cash Flow

-$4.59M

+2.0%

Operating Cash Flow

-$4.59M

+2.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BLPHBellerophon Therapeutics, Inc.
$0.01-36.84%
TFFPTFF Pharmaceuticals, Inc.
$0.07-60.05%
KERNAkerna Corp.
$0.31+36.94%
ATLNAtlantic International Corp.
$0.90+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About VIRI

What is the current price of Dogwood Therapeutics?

Dogwood Therapeutics is trading at N/A per share.

What is the 52-week range for Dogwood Therapeutics?

Over the past 52 weeks, Dogwood Therapeutics has traded between N/A and N/A.

How much debt does Dogwood Therapeutics have?

As of the most recent reporting period, Dogwood Therapeutics reported total debt of $144.93K.

How much cash does Dogwood Therapeutics have on hand?

Dogwood Therapeutics reported $13.23M in cash and cash equivalents in its most recent financial results.

What is Dogwood Therapeutics’s dividend yield?

Dogwood Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services